Aortic Valve Insufficiency

Nuance Communications, part of Microsoft, announced Friday that its Dragon Ambient eXperience Copilot automates clinical documentation during patient appointments in Meditech Expanse electronic health records. WHY IT MATTERS As a partner and a member of the Meditech Alliance Program, Nuance already supports the Expanse EHR with workflow assistance and documentation to help alleviate clinician burnout and improve patient care at the point of care, Nuance said in its announcement. The addition DAX Copilot is an extension of Nuance and Meditech's ongoing collaboration through previous integration with Nuance's cloud-based Dragon Medical One speech recognition software – which earned Best in KLAS four years running. The Dragon Medical platform enables clinicians to use their voices to update patient and clinical information as well as access patient information in EHRs, while DAX Copilot gives healthcare organizations the ability to adopt AI-powered clinical documentation applications at scale. By leveraging unobtrusive generative artificial intelligence and ambient speech recognition technologies during live patient visits, doctors can eliminate manual data entry and immediately review the automated clinical documentation in the Meditech EHR. Generative AI backed by Microsoft resources enhances Meditech's investments in Dragon Medical, said Robert Dahdah, corporate vice president of global health and life sciences and Microsoft, in a statement. THE LARGER TREND Nuance first announced its AI virtual assistance for healthcare technology in 2017 while Meditech, one of the largest EHR developers, has explored an array of AI initiatives and partnerships over the last few years. In 2021, the EHR vendor partnered with Google to adopt advanced natural language processing and large language models. Then in October, Helen Waters, chief operating officer, told Healthcare IT News that the company was using conversational AI in its virtual assistant to automate tasks and augment clinical decision-making , such as for searching patient charts and placing orders. "We carefully evaluate various types of AI," she explained. "We determine which AI can provide the strongest stability to improve the end-user experience and, obviously, more importantly, care outcomes," and "judiciously incorporate those capabilities" into workflows to support health systems in their objectives. Nuance previously announced the integration of DAX Copilot into Epic EHRs in January after a six-month testing phase. According to the company, clinicians surveyed reported a significant reduction in administrative burden with access to the genAI tool. Also, 70% reported that embedded AI in the EHR reduced feelings of burnout and cut time spent on clinical documentation by 50%. "Our clinicians say that DAX Copilot enhances the already vital role of the Epic EHR by making clinical documentation an intuitive and straightforward part of providing high-quality patient care," said Brent Lamm, chief information officer of UNC Health. ON THE RECORD "With DAX Copilot, we will extend our support for conversational and ambient AI to further reduce the documentation burden on today's busy clinicians," Jeff Kimball, Meditech associate vice president, said in a statement. "DAX Copilot is well-aligned with MEDITECH's strategy to accelerate innovation and fundamentally improve physician and patient experiences, clinical efficiency and healthcare costs and outcomes," Dahdah added. Andrea Fox is senior editor of Healthcare IT News. Email: afox@himss.org Healthcare IT News is a HIMSS Media publication.

The J-Valve system, which has FDA breakthrough device status, is intended for transcatheter aortic valve replacement procedures Genesis MedTech finishes enrollment in TAVR study of J-Valve system. (Credit: valelopardo from Pixabay) Singapore-based Genesis MedTech has concluded the enrollment for the US Early Feasibility Study (EFS) of its J-Valve Transfemoral (TF) System involving patients with severe aortic regurgitation (AR). Developed by JC Medical, the American subsidiary of Genesis MedTech, the J-Valve system is intended for transcatheter aortic valve replacement (TAVR) procedures. The system has breakthrough device designation from the US Food and Drug Administration (FDA) to treat severe native AR and AR-dominant mixed aortic valve disease. According to Genesis MedTech, a cardiac team evaluates patients to determine if they are high-risk candidates for surgical aortic valve replacement and suitable for the device. The procedure with the device is executed via a minimally invasive transfemoral method, thereby eliminating the need for extracorporeal circulation or open-heart procedures. Genesis MedTech stated that the J-Valve TF System’s design and features are suitable for patients with aortic valve regurgitation, as there are presently no authorised treatments for this condition in the US. Genesis MedTech North America vascular intervention president and JC Medical CEO Mark Turco said: “This accomplishment would not have been possible without the dedicated efforts of the investigators and research teams involved. “We look forward to the data and learnings as well as the initiation of our upcoming Pivotal Trial.” The FDA-accepted EFS study enrolled patients from five locations across the US. It focuses on evaluating symptomatic individuals having severe AR. The last patient was registered at the MedStar Washington Hospital Center in Washington, DC. Genesis MedTech said that the patients who met the inclusion criteria were administered with treatment using the J-Valve TF system. The results from this clinical experience are expected to be shared later this year. In September last year, the medical device company received approval from China’s National Medical Products Administration (NMPA) for the market launch of its absorbable sutures with antibacterial protection.

JC Medical reports milestone accomplishment with its TAVR device BURLINGAME, Calif., Feb. 5, 2024 /PRNewswire/ -- Genesis MedTech, a leading medical device company, today announced the completion of enrollment in its United States Early Feasibility Study (EFS) using its dedicated transcatheter aortic valve replacement (TAVR) system, J-Valve™ Transfemoral (TF) System. Finalizing the EFS marks another significant milestone for Genesis MedTech and its U.S.-based subsidiary JC Medical. The FDA approved EFS trial involved patient enrollment at five centers across the United States. The trial focused on evaluating symptomatic individuals with severe Aortic Regurgitation. The last patient was successfully enrolled by Drs. Ron Waksman and Lowell Satler, MedStar Washington Hospital Center, Washington, DC. The EFS Co-Principal Investigators were Dr. Dean Kereiakes, President of the Christ Hospital Heart and Vascular Institute, Cincinnati, OH. and Dr. Michael Reardon, Professor of Cardiothoracic Surgery, Allison Family Distinguished Chair of Cardiovascular Research at Houston Methodist Hospital, Houston, TX. Patients meeting the inclusion criteria received treatment using the J-Valve™ TF system. The outcomes of this clinical experience will be presented later this year. "TAVR has proven results for patients with Aortic Stenosis. An unmet need remains for patients with Aortic Regurgitation," Dr. Reardon commented. "The J-Valve™ being a dedicated TAVR design has shown promise in treating patients with aortic regurgitation. We are pleased with our findings to date from our EFS and look forward to the successful initiation of the pivotal trial." Developed by JC Medical, the J-Valve™ TF System has been granted Breakthrough Device designation for the proposed indication of treating severe native aortic regurgitation (AR) and AR-dominant mixed aortic valve disease. Patients are assessed by a heart team to be eligible for the device and at high risk for surgical aortic valve replacement. The procedure is performed through a minimally invasive transfemoral approach, without the need for open-heart procedure or extracorporeal circulation. The innovative design and features of the J-Valve™ TF System can potentially help patients that suffer from aortic valve regurgitation, currently lacking approved treatment options in the United States. "This accomplishment would not have been possible without the dedicated efforts of the investigators and research teams involved," stated Dr. Mark A. Turco, CEO of JC Medical and President of Vascular Intervention North America at Genesis MedTech. "We look forward to the data and learnings as well as the initiation of our upcoming Pivotal Trial." The J-Valve ™ TF System is an investigational device in the United States and Canada. ABOUT GENESIS MEDTECH & JC MEDICAL Based in Burlingame California, JC Medical Inc., under Genesis MedTech Group, is a transcatheter based cardiovascular company that is primarily engaged in the design and development of transcatheter valve replacement products for the minimally invasive treatment of structural heart diseases. Genesis MedTech Group is a medical device company headquartered in Singapore. Founded by a group of professionals and entrepreneurs with MedTech experience globally, the company's product portfolio focuses on multi-therapy medical device products for emerging markets with sales and distribution through its established commercial network. Genesis MedTech Group covers the entire industry value chain of research and development, production, quality management, supply chain, marketing, and sales. For more information, visit & SOURCE Genesis MedTech